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Table 1.  CB1R affinity (Ki) and CB1R-mediated G-protein efficacy (Emax) and ligand potency (EC50) 
values of KYNA and the CB1R selective ACEA alone and in combination with KYNA. Ki values of 
the non-selective CBR ligand WIN55,212-2 and the CB2R selective CB65 ligand is also indicated for 
control and for comparison. The indicated parameters were calculated from the concentration-effect 
curves presented in Figure 2A (Ki) and B (Emax, EC50) and were statistically analyzed as discussed in 
section ERROR!  REFERENCE SOURCE NOT FOUND.. 
  CB1R affinity 
([3H]WIN55,212-2 binding)  
G-protein activity 
([35S]GTPγS binding) 
Compounds  Ki ± S.E.M. (nM) n  Emax ± S.E.M. (%) EC50 ± S.E.M. (nM) n 
KYNA  not relevant1 4  100.9 ± 1.22 not relevant1 3 
ACEA  202.9 ± 55.28 4  170.2 ± 6.55 137.72 ± 53.22 3 
ACEA + 10 µM KYNA  214.92 ± 40.26 4  164.4 ± 6.43 129.12 ± 52.55 3 
WIN55,212-2  3.74 ± 0.89 4  N.D. 
CB65  >1000 4  N.D. 
1:  Total specific binding (100%) was not altered significantly (one-sample t test with 100 % theoretical value), thus 
K i value calculation is not relevant 
2:  [3H]WIN55,212-2 binding was only reduced to 62 %. 
N.D.: not determined. 
 
Table 2. KYNA concentration levels in plasma and CSF following systemic KYNA chronic 
treatment (i.p., 9 days, 128 mg/kg/day). Experiments were analyzed and performed as described in 
section ERROR! REFERENCE SOURCE NOT FOUND. and ERROR! REFERENCE SOURCE NOT 
FOUND., respectively. 
Plasma  CSF 
Concentration ± S.E.M. (nM)  Concentration ± S.E.M. (nM) 
Vehicle KYNA  Vehicle KYNA 
63.95 ± 7.95 
 (n=5) 
307.58 ± 60.44** 
(n=5) 
 
3.32 ± 1.32### 
(n=5) 
10.69 ± 2.04*/## 
(n=4) 
*:  indicates the significant difference compared to vehicle (unpaired t test, two-
tailed P value). 
#: indicates the significant difference compared to their corresponding group 
measured in the plasma (unpaired t test, two-tailed P value). 
 
Table 3. The effect of long-term systemic KYNA treatment (i.p., 9 days, 128 mg/kg/day) compared to 
vehicle on CB1R-coupled G-protein activity in rat brain membranes described by the indicated 
parameters obtained from [35S]GTPγS binding assays. CB1R was stimulated by the highly CB1R 
selective agonist ACEA and inverse agonist rimonabat. The table highlights the non-specific binding 
(NS), basal activity (Basal) and maximum efficacy (Emax) levels of CB1R-coupled G-protein activity 
upon receptor stimulation given in specifically bound [35S]GTPγS of protein content. Emax levels and 
ligand potency (EC50) values were also calculated when data were normalized to basal activity levels 
(100 %) to see the overall performance of the ligands. Data were obtained from concentration-effect 
curves shown in Fig. 3 and statistically analyzed based on section ERROR! REFERENCE SOURCE 
NOT FOUND..       
   Normalized to protein content  Normalized to basal activity 
Compounds Treatment (n) 
 NS ± S.E.M. 
(fmol/mg) 
Basal ± S.E.M. 
(fmol/mg) 
Emax ± S.E.M. 
(fmol/mg) 
 
Emax ± S.E.M. 
(%) 
EC50 ± S.E.M. 
(nM) 
ACEA Vehicle (5)  19.89 ± 1.89 40.43 ± 8.52 61.76 ± 14.57   153.3 ± 6.99 1059.25 ± 626.93 
 KYNA (8)  23.77 ± 1.39  85.18 ± 13.12* 124 ± 15.95*  152.6 ± 5.6 1713.96 ± 902.28 
Rimonabant Vehicle (7)  20.6 ± 1.13 50.56 ± 2.85 12.1 ± 3.78  14.8 ± 6.86 1870.68 ± 601.76 
 KYNA (7)  22.92 ± 1.55 81.73 ± 2.74*** 26.6 ± 4.41*  27.91 ± 4.74 2004.47 ± 478.91 
*: significant difference compared to vehicle treated (unpaired t test, two-tailed P value; *: P < 0.05; ***: P < 0.001 
NS: non-specific binding 
 
Table 4. The effect of long-term systemic KYNA treatment (i.p., 9 days, 128 mg/kg/day) on CB1R 
maximum binding capacity (Bmax) and binding affinity (dissociation constant; Kd) in saturation binding 
assays using [3H]WIN55,212-2 radioligand to detect CB1Rs in rat brain membranes. Data were 
obtained and analyzed from concentration-effect curves presented in Fig. 4 as described in section 
ERROR! REFERENCE SOURCE NOT FOUND..     
  [3H]WIN55,212-2 saturation binding 
Treatment (n)  Bmax ± S.E.M. (fmol/mg) Kd ± S.E.M. (nM) 
Vehicle (4)   1339.25 ± 54.79 9.17 ± 1.04 
KYNA (4)  1879.09 ± 54.44*** 11.69 ± 0.91 
*:  significant difference compared to vehicle treaed (unpaired t test, 
two-tailed P value; ***: P < 0.001) 
 
Table 5. The effect of long-term systemic KYNA treatment (i.p., 9 days, 128 mg/kg/day) compared to 
vehicle on CB1R-coupled G-protein activity in rat cortex, hippocampus and brainstem described by the 
indicated parameters obtained from [35S]GTPγS binding assays. CB1R was stimulated by the highly 
CB1R selective agonist ACEA in increasing concentrations. The table highlights the non-specific 
binding (NS), basal activity (Basal) and maximum efficacy (Emax) levels of CB1R-coupled G-protein 
activity upon receptor stimulation given in specifically bound [35S]GTPγS of protein content. Emax 
levels and ligand potency (EC50) values were also calculated when data were normalized to basal 
activity levels (100 %) to see the overall performance of the ligand. Data were obtained from 
concentration-effect curves shown in Fig. 5 and statistically analyzed based on section ERROR! 
REFERENCE SOURCE NOT FOUND..       
   Normalized to protein content  Normalized to basal activity 
Brain region Treatment (n) 
 NS ± S.E.M. 
(fmol/mg) 
Basal ± S.E.M. 
(fmol/mg) 
Emax ± S.E.M. 
(fmol/mg) 
 
Emax ± S.E.M. 
(%) 
EC50 ± S.E.M. 
(nM) 
Cortex Vehicle (3)  5.53 ± 0.18 60.09 ± 6.28 96.03 ± 12.69   159.8 ± 5.92 189.23 ± 74.34 
 KYNA (3)  5.47 ± 0.03  61.28 ± 3.39 97.96 ± 7.19  160.2 ± 6.4 243.22 ± 97.66 
Hippocampus Vehicle (6)  6.49 ± 0.44 84.7 ± 6.45 161.7 ± 8.71  193.1 ± 4.56 130.32 ± 24.69 
 KYNA (5)  7.42 ± 0.25 119.5 ± 4.46** 217.3 ± 11.93**  186.7 ± 6.28 161.81 ± 38.66 
Brainstem Vehicle (6)  9.91 ± 3.02 26.34 ± 2.84 36.39 ± 4.17  129.8 ± 1.92 91.41 ± 20.23 
 KYNA (4)  9.91 ± 4.49 26.52 ± 6.73 33.18 ± 9.55  130.3 ± 1.92 96.16 ± 22.88 
*: significant difference compared to vehicle treated (unpaired t test, two-tailed P value; **: P < 0.01) 
 
Table 6. The effect of long-term systemic KYNA treatment (i.p., 9 days, 128 mg/kg/day) in rat 
hippocampus on CB1R maximum binding capacity (Bmax) and binding affinity (dissociation constant; 
Kd) in saturation binding assays using [
3H]WIN55,212-2 radioligand to detect CB1Rs. Data were 
obtained and analyzed from concentration-effect curves presented in Fig. 6 as described in section 
ERROR! REFERENCE SOURCE NOT FOUND..     
  [3H]WIN55,212-2 specific binding 
Treatment (n)  Bmax ± S.E.M. (fmol/mg) Kd ± S.E.M. (nM) 
Vehicle (4)   1069.16 ± 96.83  13.39 ± 2.98 
KYNA (4)  1403.23 ± 75.36* 16.74 ± 2.07 
*:  significant difference compared to vehicle treaed (unpaired t test, 
two-tailed P value) 
 






HIGHLIGHTS: 
• Kynurenic acid (KYNA) does not interact directly with CB1Rs. 
• Chronic, systemic KYNA treatment elevates KYNA CSF and plasma levels. 
• The same treatment increases the amount of functional CB1Rs in the whole brain.  
• The treatment does not affect the binding and the activity of the receptor. 
• Such results also apply to the hippocampus, but not to the cortex or brainstem. 
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ABSTRACT  
 
Kynurenic acid (KYNA) is one of the most significant metabolite of the kynurenine 
pathway both in terms of functional and potential therapeutic value. It is an N-methyl-D-aspartate 
(NMDA) receptor antagonist, but it can also activate the G-protein coupled receptor 35 (GPR35), 
which shares several structural and functional properties with cannabinoid receptors. Previously 
our group demonstrated that systemic chronic KYNA treatment altered opioid receptor G-protein 
activity. Opioid receptors also overlap in many features with cannabinoid receptors. Thus, our 
aim was to examine the direct in vitro and systemic, chronic in vivo effect of KYNA on type 1 
cannabinoid receptor (CB1R) binding and G-protein activity. 
Based on competition and [35S]GTPγS G-protein binding assays in rat brain, KYNA alone 
did not show significant binding towards the CB1R, nor did it alter CB1R ligand binding and 
agonist activity in vitro. When rats were chronically treated with KYNA (single daily, i.p., 128 
mg/kg for 9 days), the KYNA plasma and cerebrospinal fluid levels significantly increased 
compared to vehicle treated group. Furthermore, in G-protein binding assays, in the whole brain 
the amount of G-proteins in basal and in maximum activity coupled to the CB1R also increased 
due to the treatment. At the same time, the overall stimulatory properties of the receptor remained 
unaltered in vehicle and KYNA treated samples. Similar observations were made in rat 
hippocampus, but not in the cortex and brainstem. In saturation binding assays the density of 
CB1Rs in rat whole brain and hippocampus were also significantly enhanced after the same 
treatment, without significantly affecting ligand binding affinity.  
Thus, KYNA indirectly and brain region specifically increases the abundance of functional 
CB1Rs, without modifying the overall binding and activity of the receptor. Supposedly, this can 
be a compensatory mechanism on the part of the endoca nabinoid system induced by the long-
term KYNA exposure. 
 
 
 
 
 
 
 
 
 
Keywords: type 1 cannabinoid receptor; kynurenic acid; G-protein; [35S]GTPγS binding; 
radioligand binding; hippocampus 
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ABBREVIATIONS: 
[35S]GTPγS, guanosine-5’-O-(3-[35S]thio)triphosphate  
ACEA, arachidonyl-2'-chloroethylamide 
BBB, blood-brain-barrier  
Bmax, maximum binding capacity 
CB1R , type 1 cannabinoid receptor 
CNS, central nervous system 
CSF, cerebrospinal fluid 
EC50, 50 % effective concentration 
ECS, endocannabinoid system 
EGTA, ethyleneglycol-tetraacetate 
Emax, maximum efficacy 
GDP, guanosine 5’-diphosphate 
GPCR, G-protein coupled receptor 
GPR35, G-protein coupled receptor 35  
GTP, guanosin 5’-triphosphate 
GTPγS, Guanosine-5’-O-[γ-thio] triphosphate 
HPLC, high-performance liquid chromatography 
Kd, dissociation constant 
K i, inhibitory constant 
KP, kynurenine pathway 
KYNA, kynurenic acid 
L-KYN, L-kynurenine 
NMDAR, N-methyl-D-aspartate receptor 
Tris-HCl, tris-(hydroxymethyl)-aminomethane hydrochloride 
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1 INTRODUCTION 
The endocannabinoid system (ECS) is comprised of the lipid-like endogenous cannabinoids 
(endocannabinoids), their synthetizing and metabolizing enzymes and the G-protein coupled 
cannabinoid receptors (CB1R and CB2R) , which mediates their effects (Rodríguez de Fonseca et 
al., 2005). The ECS is a major neuromodulator system maintaining the tones of several 
physiological processes (Rodríguez de Fonseca et al., 2005). The CB1R is the most abundant G-
protein coupled receptor (GPCR) in the central nervous system (CNS), its density is comparable 
to that of the glutamate, γ-aminobutyric acid (GABA) and dopamine receptors (Herkenham et al., 
1990; Matsuda et al., 1990; Piomelli, 2003). It can also be found in the periphery such as in 
adipose tissues, cardiovascular and gastrointestinal system (Maccarrone et al., 2015; Pagotto et 
al., 2006). CB1Rs belong to the class A GPCR superfamily and they mostly couple to the Gi/o 
type inhibitory G-protein. Thus, their activation ih bits cyclic adenosine monophosphate 
(cAMP) production and L-type Ca2+ channel activity as well as stimulates K+ channels (Howlett 
et al., 2002). Overall these signal transductions will eventually inhibit the release of several types 
of neurotransmitters, such as acetylcholine, GABA, noradrenaline or dopamine (Howlett et al., 
2002). These induced changes allow the CB1Rs to be involved for instance in the regulation of 
mood, energy balance and endocrine functions (Maccarrone et al., 2015; Pagotto et al., 2006; 
Pertwee, 2009). 
The kynurenine pathway (KP) is the main route of tryptophan (Fig. 1) catabolism and 
kynurenic acid (KYNA; Fig. 1) - a side product of L-kynurenine (L-KYN; Fig. 1) - is recognized 
as a potent neuroprotective molecule in several experimental models (Carrillo-Mora et al., 2010; 
Chen et al., 2011; Knyihar-Csillik et al., 2008; Lee t al., 2008; Oláh et al., 2013; Silva-Adaya et 
al., 2011). It has been also well documented that the level of KYNA concentration in the brain is 
relevant in multiple neurological diseases (Bortz et al., 2017; Vécsei et al., 2013). KYNA is an 
endogenous ligand for multiple receptors, such as the N-methyl-D-aspartate receptor (NMDAR) 
and other ionotropic glutamate receptors (Birch et al., 1988; Perkins and Stone, 1985), and the G-
protein coupled receptor 35 (GPR35) (Wang et al., 2006). 
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Figure 1. Chemical structure of L-tryptophan, L-kynurenine and kynurenic acid. 
Previously we demonstrated that chronic KYNA treatment significantly altered opioid 
receptor G-protein activity depending on receptor type and brain region, without binding directly 
to the opioid receptors (Zádor et al., 2014b). This effect also appeared after acute treatments, and 
the involvement of the NMDAR was also demonstrated (Samavati et al., 2017). In addition,  
opioid peptides incorporating L-KYN and KYNA have been synthesized and characterized 
recently, which compounds displayed significant opioid receptor binding, agonist activity and 
antinociceptive effect (Szűcs et al., 2020). Opioid receptors share similar structural and functional 
properties with cannabinoid receptors (Viganò et al., 2005), moreover their heterodimerization 
can be exploited with opioid-cannabinoid bivalent compounds for the development of safer 
analgesics (Dvorácskó et al., 2019; Fernández-Fernández et al., 2014; Le Naour et al., 2013; 
Mollica et al., 2017). More importantly, cannabinoid receptors also resemble to the KYNA 
activated GPR35 in G-protein signaling, structure, distribution and function (Shore and Reggio, 
2015; Wang et al., 2006). Furthermore, exogenous cannabinoids are known to alter the activity of 
certain enzymes of the KP in a cannabinoid receptor-dependent manner in peripheral blood 
mononuclear cells (Jenny et al., 2009). Also, acute te rahydrocannabinol (THC) treatment has 
been shown to reduce extracellular levels of KYNA through the CB1R in brain reward processing 
areas (Secci et al., 2018). Thus, a potential cross-talk might be present between the members of 
KP (enzymes, metabolites) and the ECS. This is supported by overlapping functions in certain 
mechanisms such as dopamine, glutamate or GABA neurotransmission regulation (Beggiato et 
al., 2014; Fernández-Ruiz et al., 2010; Javitt et al., 2011; Stone et al., 2007) or immune 
regulation  (Maccarrone et al., 2015; Mándi and Vécsei, 2012). Finally, Beggiato and co-workers 
recently demonstrated that long-term prenatal THC exposure significantly increases KYNA 
levels in the prefrontal cortex of adult rats (Beggiato et al., 2020). In the same study they also 
showed that after a low dose, acute and systemic KYN treatment in adulthood, the increase of 
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KYNA levels in the prefrontal cortex was more pronou ced in prenatally THC-exposed rats 
(Beggiato et al., 2020). 
Considering the above mentioned data we designed a set of experiments to investigate for 
the first time the direct binding/interaction of KYNA to the CB1R in receptor binding and G-
protein activity measurements. The CB1R was chosen because it is the most widely studied 
cannabinoid receptor of the ECS. Additionally, the effect of a long-term KYNA treatment was 
examined on G-protein activity and CB1R binding, using the same treatment protocol as applied 
for opioid receptors previously (Zádor et al., 2014b). In these experiments, initially whole brain 
membranes were investigated after the treatment. The cortex, the hippocampus and the brainstem 
was further analyzed the same way, since these regions are rich in CB1Rs (Herkenham et al., 
1990) and/or mediate important cellular functions. 
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2 MATERIALS AND METHODS 
2.1 Chemicals 
Tris-HCl, ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), 
NaCl, MgCl2 x 6H2O, guanosine diphosphate (GDP), the guanosine triphosphate (GTP) analogue 
GTPγS and kynurenic acid (KYNA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Fatty acid free bovine serum albumin (BSA) was purchased from Serva (Heidelberg, Germany). 
The CB1R specific agonist and inverse agonist arachidonyl-2'-chloroethylamide (ACEA) and 
rimonabant, respectively and the non-selective cannabi oid receptor agonist WIN55,212-2 were 
purchased from Tocris Bioscience (Budapest, Hungary). The radiolabeled GTP analogue, 
[35S]GTPγS (specific activity: 37 TBq/mmol; 1000 Ci/mmol) was obtained from Hartmann 
Analytic (Braunschweig, Germany). The tritiated WIN55,212-2 ([3H]WIN55,212-2) was 
radiolabeled in the Laboratory of Chemical Biology (Biological Research Centre, Szeged, 
Hungary; specific activity: 485 GBq/mmol) (Szűcs et al., 2016). The UltimaGoldTM MV aqueous 
scintillation cocktail was purchased from PerkinElmer (Per-form kft, Budapest, Hungary). 
KYNA for receptor assays was dissolved in highly pure distilled water, while cannabinoid 
compounds were dissolved in dimethyl sulfoxide. Allcompounds were stored in 1 mM stock 
solution at -20 ˚C. All chemicals and reagents used for the high-performance liquid 
chromatography (HPLC) measurements were of analytic or HPLC grade, and they were 
acquired from Sigma-Aldrich (St. Louis, MO, USA). The internal standard used for the 
fluorescent detector, was synthesized at the Department of Pharmaceutical Chemistry, University 
of Szeged, as detailed elsewhere (Cseh et al., 2019). 
2.2 Animals, treatments and sample extraction 
Throughout the study, 47 male Sprague-Dawley rats were used; the animals were 8-10 
weeks of age, with an average body weight of 250-350 g. For HPLC measurements 6, for whole 
brain and brain region specific receptor binding assay  8 and 7 animals per group were used, 
respectively. In KYNA affinity and G-protein activity measurements overall 5 animals were 
sacrificed. The animals were bred and maintained under standard laboratory conditions on a 12-h 
dark 12-h light cycle at 22-24 °C and ~55% relative humidity with free access to water and food 
pellets. All experimental procedures were carried out in accordance with the European 
Communities Council Directive (2010/63/EU), and the Hungarian Act for the Protection of 
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Animals in Research (XXVIII.tv. 32.§). We did the bst effort to minimize the number of animals 
and their suffering. 
KYNA was dissolved in saline and the pH of the soluti ns was adjusted to 7.4 with 1 N 
NaOH.  Rats were divided into two groups, KYNA and vehicle treated. KYNA was administered 
intraperitoneal (i.p.) in a dose of 128 mg/kg/day in a volume of 1 ml to each animal. The animals 
received the injections once a day in the morning, at the same time for 9 consecutive days based 
on our previous study (Zádor et al., 2014b). The control group received vehicle, which was 0.9 % 
saline. The treatments were well tolerated by the anim ls.  
Four hours after the last injection, on the 9th day, r ts were deeply anesthetized with 
chloral-hydrate (Sigma-Aldrich, Budapest, Hungary). Prior to perfusion, the cerebrospinal fluid 
(CSF) was taken quickly from the suboccipital cistern of rats with 23G needle to Eppendorf tubes 
(rats were placed to the stereotaxic setup in order to fix their head). Venous blood was collected 
from the left of the heart chamber to a tube containing EDTA as anticoagulant. Transcardial 
perfusion was performed with PBS (100 ml, 0.1 M, pH 7.4). The perfused brains were removed 
rapidly and in case of vehicle and KYNA treated samples the cerebellum was dissected, and the 
remaining brain area was stored or the cortex, hippocampus and brainstem were excised. For 
characterizing CB1R binding and activity in vitro in the presence of KYNA, untreated perfused 
whole brain samples were used. Samples were stored at -80 °C until preparation for the in vitro 
experiments. 
2.3 Receptor binding assays 
2.3.1 Membrane preparation 
The tissue samples were handled for membrane preparation according to Benyhe and co-
workers (Benyhe et al., 1997). The membrane homogenates were used both for [35S]GTPγS 
binding assays and for saturation binding studies according to Zádor and co-workers (Zádor et 
al., 2014a). In brief, the samples from the same treatment group and brain region were pooled 
together and were homogenized, centrifuged in ice-cold TEM buffer (50 mM Tris-HCl, 1 mM 
EGTA, 3 mM MgCl2, 100 mM NaCl, pH 7.4) and then incubated at 37 
oC for 30 min in a shaking 
water-bath. After incubation, the centrifugation was repeated and the final pellet was again 
suspended in TEM buffer (pH 7.4). From hippocampus samples membrane fractions were not 
prepared; they were only homogenized. This was to limit the number of sacrificed animals. Due 
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to the small size of the rat hippocampus, unnecessary number of animals would have been 
sacrificed for the assays to obtain membrane fractions with adequate protein content. Protein 
concentrations of the samples were measured by the Bradford method and samples were diluted 
to obtain the appropriate amount for the assay as described below. Samples were stored -80 oC 
for further use. 
2.3.2 Radioligand competition binding assays 
In competition binding assays the specific binding of a receptor selective radioligand is 
measured in the presence of increasing concentrations of an unlabeled compound (Frey and 
Albin, 2001). The concentration dependent decrease of radioligand specific binding provides 
information of the binding affinity of the unlabeled compound by determining the concentration 
range of 50 % inhibition and the inhibitory constant (IC50, Ki). 
  Whole brain membrane homogenates containing 0.5 mg/ml of protein were incubated in 
the presence of 50 mM Tris-HCl, 2.5 mM EGTA, 5 mM MgCl2 and 0.5 mg/ml fatty acid-free 
BSA (pH 7.4) together with increasing concentrations (0.1 nM-10 µM) of KYNA, ACEA (in the 
absence or presence of 10 µM KYNA), WIN55,212-2 andCB65, with ~ 1-3 nM concentrations 
of [3H]WIN55,212-2. The non-specific and total binding was determined in the presence of 10 
µM unlabeled WIN55,212-2 and in the absence of unlabeled compounds, respectively. Following 
a 60 min incubation at 30 oC, the reaction was terminated by rapid filtration u der vacuum 
(Brandel M24R Cell Harvester), and washed three tims with ice-cold 50 mM Tris-HCl, 2.5 mM 
EGTA, 5 mM MgCl2 and 0.5 mg/ml fatty acid-free BSA (pH 7.4) through W atman GF/B glass 
fiber filters (GE Healthcare Life Sciences through Izinta Kft., Budapest, Hungary). The 
radioactivity of the filters was counted in UltimaGoldTM MV aqueous scintillation cocktail with 
Packard Tricarb 2300TR liquid scintillation analyzer. 
2.3.3 Functional [35S]GTPγS binding assays 
In [35S]GTPγS binding experiments the GDP→GTP exchange of the Gα protein is 
monitored in the presence of a given compound in increasing concentrations to measure ligand 
potency (EC50) and the maximal effect (efficacy; Emax) of receptor G-protein (Strange, 2010). The 
nucleotide exchange is monitored by a radioactive, non-hydrolysable GTP analog, [35S]GTPγS. 
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The functional [35S]GTPγS binding experiments were performed as previously described 
(Selley et al., 1997; Traynor and Nahorski, 1995), with modifications. Briefly, the brain samples 
containing 30 µg/ml protein were incubated at 30 ˚C for 60 min in Tris-EGTA buffer (pH 7.4) 
composed of 50 mM Tris-HCl, 1 mM EGTA, 3 mM MgCl2, 100 mM NaCl contained 0.05 nM 
[35S]GTPγS and increasing concentrations (0.1 nM-10 µM) of KYNA, ACEA (in the presence or 
absence of 10 µM KYNA) or rimonabant and excess GDP (30 µM) in a final volume of 1 ml. 
Such assay protocol has been shown to be optimized for monitoring Gi/o-type G-proteins 
(DeLapp et al., 2004). Total binding was measured in the absence of ligands, while non-specific 
binding was determined in the presence of 10 µM unlabeled GTPγS. The bound and unbound 
[35S]GTPγS were separated by rapid filtration under vacuum (Brandel M24R Cell Harvester) 
through Whatmann GF/B glass fibers and washed threeimes with ice-cold 50 mM Tris-HCl (pH 
7.4). The radioactivity of the filters was measured as described in section 2.3.2. 
2.3.4 Saturation binding assays 
With saturation binding experiments we can determine the maximum binding capacity of a 
receptor (Bmax), which also indicates the density of the given receptor in the examined tissue 
sample (Frey and Albin, 2001). This is done by saturating the receptor with a radioligand specific 
to that receptor protein applying it in increasing concentrations. Additionally, the affinity of the 
radioligand can also be determined with the dissociation constant (Kd). 
 In saturation binding assays membrane preparations c taining 0.4 mg/ml of protein were 
incubated in the presence of 50 mM Tris-HCl, 2.5 mM EGTA, 5 mM MgCl2 and 0.5 mg/ml fatty 
acid-free BSA (pH 7.4), together with increasing con entrations of [3H]WIN55,212-2 (0.13–65 
nM) in the absence (total binding) or presence (non-specific binding) of 10 µM WIN55,212-2. 
Following incubation (60 min, 30 ˚C), the bound and unbound [3H]WIN55,212-2 were separated 
and the radioactivity of the samples were measured as escribed in section 2.3.2. 
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2.4 HPLC measurements 
Validated HPLC methods were performed by an Agilent 1100 HPLC system (Santa Clara, 
CA, USA), coupled with UV detector (UVD) and fluorescence detector (FLD). The 
chromatographic separation, and the validation process was described elsewhere (Cseh et al., 
2019). Briefly, the brain regions were homogenized in 0.5 M perchloric acid (PCA), at 1:5 w/v 
containing the internal standards (ISs) 3-nitro-L-tyrosine (3-NLT) and 4-hydroxyquinazoline-2-
carboxylic acid (HCA) at a final concentration of 2 µM and 100 nM, respectively. The precipitate 
was separated by centrifugation for 10 min at 12000 rpm at 4 °C. As for the plasma and CSF 
samples, both were deproteinized with 0.5 M PCA soluti n, 1:1 v/v and 5:6 v/v respectively, then 
the above-mentioned centrifugation process was applied. Afterwards, the chromatographic 
separations were performed on a reversed-phase C18 column (Kinetex, 150×4.6mm I.D., 5 μm 
particle size; Phenomenex Inc., Torrance, CA, USA) with a mobile phase composition of 200 
mM zinc acetate, at final pH of 5.8 for brain tissue samples and 6.2 for plasma and CSF samples, 
with a final concentration of 5 % of acetonitrile in each case. Blinded HPLC measurements were 
conducted to eliminate experimental biases. 
2.5 Data analysis 
In receptor binding assays, the specific binding of the given radiolabeled compound 
([3H]WIN55,212-2, [35S]GTPγS) was calculated by subtracting the non-specific bnding from the 
total binding. Data were normalized either to total specific binding or either to protein content 
presented in fmol/mg. Total specific binding was set 100 %, which represented the basal activity 
level of G-protein in the case of [35S]GTPγS measurements. The means ± S.E.M. (standard error 
of mean) of data sets were plotted in the function of the applied ligand concentration in 
logarithmic scale (except for saturation binding) and were fitted with GraphPad Prism 7.0 
(GraphPad Prism Software Inc., San Diego, CA), by non-linear regression. For competition 
binding assays the ‘One-site competition’ equation was used to determine the IC50 value 
(unlabeled ligand affinity) and to calculate the inhibitory constant (Ki) value according to the 
Cheng-Prusoff equation (Cheng and Prusoff, 1973). Experimental data of [35S]GTPγS binding 
assays were fitted with the ‘Sigmoid dose-response’ equation to obtain maximum efficacy (Emax) 
and ligand potency (EC50) values. Saturation binding data were fitted with ‘One-site - specific 
binding’ equation to visualize maximum binding capacity (Bmax) and dissociation constant (Kd) 
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values. Additionally, in these assays non-specific binding was also plotted with linear regression 
to compare slopes. 
In the HPLC analysis, the relative peak area respones (analyte/internal standard) were 
plotted against the corresponding concentration, and the linear regression computations were 
carried out by the least square method with the R software 3.5.3 (R Core Team, 2014). 
For two data sets unpaired t test with two-tailed P value, for more than two data sets two-
way ANOVA with uncorrected Fisher’s LSD was used. One sample t-test with a hypothetical 
value of 100 % was applied when given specific binding values were compared to total specific 
binding (100 %) in receptor binding assays. Statistical analysis was performed with GraphPad 
Prism 7.0 program; significance was accepted at P < 0.05 level. 
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3 RESULTS 
3.1 KYNA does not show direct binding to the CB1R, does not induce G-protein 
activation nor does it alter CB1R ligand binding or CB1R-mediated G-protein 
stimulation  
To study the binding affinity of KYNA to CB1Rs, competition binding experiments were 
performed in rat whole brain membranes using [3H]WIN55,212-2, a non-selective cannabinoid 
radioligand. [3H]WIN55,212-2 showed adequate binding properties on the applied membrane 
homogenates, reaching a 3.3 nM Ki value in homologous displacement (Table 1, Fig. 2A). 
[3H]WIN55,212-2 in the brain preferably binds to CB1Rs, which is supported by our results 
where the CB2R selective agonist CB65 reduced the total specific b nding of [
3H]WIN55,212-2 
significantly less effectively compared to the CB1R selective ACEA (Table 1, Fig. 2A). For 
comparison 10 µM CB65 reduced total specific binding of the radioligand to 60 %, whereas in 
the presence of ACEA total specific binding reached the non-specific binding level (0 %, Table 1, 
Fig. 2A). 
KYNA on its own did not alter significantly the specific binding of the radioligand, 
indicating the lack of specific affinity towards the CB1R. When KYNA was added in 10 µM to 
ACEA, no horizontal shifts were observed in the concentration curves of the compound, 
indicating the lack of allosteric modulation. 
G-protein activity measurements were achieved using [35S]GTPγS binding assays also in 
rat whole brain membranes. In the presence of KYNA in the applied concentration range, 
[35S]GTPγS specific binding was unaltered, remaining in the basal activity level (Fig. 2B, Table 
1.). For comparison the CB1R full agonist ACEA concentration dependently increas d 
[35S]GTPγS specific binding with a maximum effectivity (Emax) of 170.2 % and a potency (EC50) 
of 137.8 nM (Table 1, Fig. 2B). Additionally, these parameters were not altered in the presence of 
10 µM KYNA (Table 1, Fig. 2B).  
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Table 1.  CB1R affinity (Ki) and CB1R-mediated G-protein efficacy (Emax) and ligand potency (EC50) 
values of KYNA and the CB1R selective ACEA alone and in combination with KYNA. Ki values of the 
non-selective CBR ligand WIN55,212-2 and the CB2R selective CB65 ligand is also indicated for contrl 
and for comparison. The indicated parameters were calculated from the concentration-effect curves 
presented in Figure 2A (Ki) and B (Emax, EC50) and were statistically analyzed as discussed in section 2.5. 
  CB1R affinity 
([3H]WIN55,212-2 binding) 
 G-protein activity  
([35S]GTPγS binding) 
Compounds  Ki ± S.E.M. (nM) n  Emax ± S.E.M. (%) EC50 ± S.E.M. (nM) n 
KYNA  not relevant1 4  100.9 ± 1.22 not relevant1 3 
ACEA  202.9 ± 55.28 4  170.2 ± 6.55 137.72 ± 53.22 3 
ACEA + 10 µM KYNA  214.92 ± 40.26 4  164.4 ± 6.43 129.12 ± 52.55 3 
WIN55,212-2  3.74 ± 0.89 4  N.D. 
CB65  >1000 4  N.D. 
1:  Total specific binding (100%) was not altered significantly (one-sample t test with 100 % theoretical value), thus Ki 
value calculation is not relevant 
2:  [3H]WIN55,212-2 binding was only reduced to 62 %. 
N.D.: not determined. 
 
 
 
 
 
Figure 2. CB1R binding affinity (A) and G-protein activity (B) of KYNA and the CB1R selective ACEA 
in the presence or absence of KYNA in concentration-response binding curves of [3H]WIN55,212-2 
competition and functional [35S]GTPγS binding assays. Assays were performed in rat brain membrane 
homogenates. Figures represent the specific binding of [3H]WIN55,212-2 or [35S]GTPγS in percentage 
(means ± S.E.M.) normalized to total specific binding (100 %, which equals to basal activity in case of G-
protein activity) in the presence of increasing concentrations of KYNA (0.1 nM - 10 µM), ACEA (A: 0.1 
nM - 10 µM; B: 0.1 nM - 1 µM), WIN55,212-2 or CB65 (0.1 nM - 10 µM). ACEA binding and G-protein 
activity was also measured in the presence of 10 µM KYNA. Total specific binding was measured in the 
absence of the indicated compounds. Dotted lines repres nt total specific binding (A) or basal activity 
level (B). Curve parameters (A: Ki; B: Emax, EC50) are indicated in Table 1. Curves were fitted as 
described in section 2.5, binding assays were performed according to section 2.3.2 and 2.3.3.  
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3.2 Chronic systemic KYNA treatment increases the KYNA CSF and plasma levels 
In order to investigate whether our applied treatment condition allows the KYNA to enter 
the CNS, we measured the KYNA concentration in the CSF and also in the plasma for 
comparison. The plasma KYNA levels significantly increased as expected (Table 2). More 
interestingly, KYNA CSF levels also increased following the treatment (Table 2), although the 
concentration levels in both groups were significantly lower as compared to the plasma levels 
(Table 2). This indicates the limited BBB penetration of KYNA. For reference, plasma and CSF 
concentrations of other metabolites of the KP were also measured, namely L-KYN and 
tryptophan. Neither of them showed significant difference following the treatment (Table S1). 
 
Table 2. KYNA concentration levels in plasma and CSF following systemic KYNA chronic treatment 
(i.p., 9 days, 128 mg/kg/day). Experiments were analyzed and performed as described in section 2.5 and 
2.4, respectively. 
Plasma  CSF 
Concentration ± S.E.M. (nM)  Concentration ± S.E.M. (nM) 
Vehicle KYNA  Vehicle KYNA 
63.95 ± 7.95 
 (n=5) 
307.58 ± 60.44** 
(n=5) 
 
3.32 ± 1.32### 
(n=5) 
10.69 ± 2.04*/## 
(n=4) 
*:  indicates the significant difference compared to vehicle (unpaired t test, two-
tailed P value). 
#: indicates the significant difference compared to their corresponding group 
measured in the plasma (unpaired t test, two-tailed P value). 
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3.3 Chronic systemic KYNA treatment significantly increases the amount of 
CB1R-coupled G-proteins in rat whole brain, without affecting the efficacy and the 
potency of the receptor and selective ligands, respectively 
In our further experiments the long-term effect of systemic KYNA treatment on CB1R-
mediated G-protein activity was investigated in [35S]GTPγS binding assays in rat whole brain 
membranes (excluding the cerebellum). CB1R was initially stimulated by the CB1R selective 
agonist ACEA in increasing concentrations (Fig. 3). In the vehicle treated group, as expected 
ACEA concentration dependently increased the level of [35S]GTPγS specifically bound to CB1R-
coupled G-protein as compared to total specifically bound [35S]GTPγS or to basal activity level 
(Table 3, Fig. 3A). The same tendency was observed in the KYNA treated group, however, the 
basal activity level significantly increased in these samples, as well as the amount of [35S]GTPγS 
specifically bound to CB1R-coupled G-protein in the individual concentration points (Fig. 3A, 
Table 3). The amount of maximally stimulated (Emax) CB1R-coupled G-proteins also significantly 
increased compared to the vehicle (Table 3). Importantly, the non-specific binding level of 
[35S]GTPγS did not change significantly between the two groups, which confirms their unaltered 
overall protein content (Table 3). 
 To examine whether the overall performance of ACEA was also changed significantly 
after the treatment, data was normalized to basal activity levels of G-proteins (100 %, Fig. 3B). 
The maximum efficacy  and the ligand potency (EC50) of the agonist ACEA was significantly not 
different (Table 3, Fig. 3B), indicating that although the amount of available CB1R-coupled G-
proteins increased in the brain, the overall performance of the ligand and the activity of CB1R-
coupled G-proteins remained the same. 
To support our results, we applied another CB1R selective ligand, namely the highly 
selective inverse agonist rimonabant. As expected, rimonabant concentration dependently 
decreased the specifically bound [35S]GTPγS to CB1R-coupled G-protein compared to basal 
activity. With rimonabant, we obtained the same results as with ACEA, namely the amount of G-
proteins and CB1R-coupled G-proteins in both basal activity and maxi al efficacy, respectively, 
significantly increased due to the KYNA treatment. These changes did not alter significantly the 
overall performance of the ligand similar to ACEA (Table 3, Fig. 3B). As expected, the basal 
activity and non-specific binding levels in vehicle and KYNA treated groups did not differ 
17 
 
significantly between rimonabant and ACEA (Table 3), which also validated the experimental set 
up.    
Table 3. The effect of long-term systemic KYNA treatment (i.p., 9 days, 128 mg/kg/day) compared to 
vehicle on CB1R-coupled G-protein activity in rat brain membranes d cribed by the indicated parameters 
obtained from [35S]GTPγS binding assays. CB1R was stimulated by the highly CB1R selective agonist 
ACEA and inverse agonist rimonabant. The table highlights the non-specific binding (NS), basal activity 
(Basal) and maximum efficacy (Emax) levels of CB1R-coupled G-protein activity upon receptor stimulation 
given in specifically bound [35S]GTPγS of protein content. Emax levels and ligand potency (EC50) values 
were also calculated when data were normalized to basal activity levels (100 %) to see the overall 
performance of the ligands. Data were obtained from c ncentration-effect curves shown in Fig. 3 and 
statistically analyzed based on section 2.5.       
   Normalized to protein content  Normalized to basal activity 
Compounds Treatment (n) 
 NS ± S.E.M. 
(fmol/mg) 
Basal ± S.E.M. 
(fmol/mg) 
Emax ± S.E.M. 
(fmol/mg) 
 
Emax ± S.E.M. 
(%) 
EC50 ± S.E.M. 
(nM) 
ACEA Vehicle (5)  19.89 ± 1.89 40.43 ± 8.52 61.76 ± 14.57   153.3 ± 6.99 1059.25 ± 626.93 
 KYNA (8)  23.77 ± 1.39  85.18 ± 13.12* 124 ± 15.95*  152.6 ± 5.6 1713.96 ± 902.28 
Rimonabant Vehicle (7)  20.6 ± 1.13 50.56 ± 2.85 12.1 ± 3.78  14.8 ± 6.86 1870.68 ± 601.76 
 KYNA (7)  22.92 ± 1.55 81.73 ± 2.74*** 26.6 ± 4.41*  27.91 ± 4.74 2004.47 ± 478.91 
*: significant difference compared to vehicle treated (unpaired t test, two-tailed P value; *: P < 0.05; ***: P < 0.001 
NS: non-specific binding 
 
 
 
 
Figure 3. The effect of long-term systemic KYNA treatment (i.p., 9 days, 128 mg/kg/day) on CB1R-
coupled G-protein activity compared to vehicle in rat brain membranes depicted in concentration-effect 
curves of [35S]GTPγS binding assays. CB1R was stimulated by the highly CB1R selective agonist ACEA 
and inverse agonist rimonabant (Rim.). Figures represent the specifically bound [35S]GTPγS of protein in 
fmol/mg (A) or in percentage normalized to basal activity leve s (100 %) (B) in the presence of increasing 
concentrations (0.1 nM-10µM) of ACEA or rimonabant. Data are presented as means ± S.E.M. Basal 
activity levels were determined in the absence of the indicated ligands. Dotted line indicates basal activity 
levels. * indicates the significant difference of ind vidual concentration points between vehicle and KYNA 
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treated samples (two-way ANOVA, uncorrected Fisher’s LSD; *: P < 0.05; **: P < 0.01; ***: P < 0.001). 
Data were fitted as described under section 2.5, assays were performed as discussed in section 2.3.3. 
3.4 Chronic systemic KYNA treatment enhances the CB1R maximum binding capacity in 
rat whole brain without altering the binding affini ty of the receptor 
In the next step, we examined whether the number of CB1R binding sites also increased 
apart from the amount of CB1Rs coupled to the G-protein in rat whole brain following chronic 
systemic KYNA treatment. Saturation binding experiments were conducted using 
[3H]WIN55,212-2 radioligand to detect CB1R binding sites by applying the radioligand in 
increasing concentration to saturate the binding sites of the receptors. In vehicle treated samples 
the amount of [3H]WIN55,212-2 specifically bound to CB1Rs concentration dependently 
increased and reached saturation, which renders the maximum binding capacity (Bmax) or the 
density of the receptor (Fig. 4, Table 4). The KYNA treatment significantly increased the amount 
of specifically bound radioligand to the receptor protein from 4.17 nM compared to vehicle 
treatment (Fig. 4). As a result, in the KYNA treated group the plateau value of the saturation 
curve significantly increased, compared to vehicle group, which indicated a significantly higher 
Bmax value and thus higher receptor density (Fig. 4, Table 4). However, the affinity of the 
radioligand (equilibrium dissociation constant, Kd), did not change significantly (Table 4). In 
both samples, the non-specific binding level of theradioligand concentration dependently and 
linearly increased, as expected (inset of Fig. 4). Additionally, the slope of the linear regression 
quantifying the non-specific binding level did not change significantly (vehicle: 27.84 ± 1.07 vs. 
KYNA: 28.53 ± 0.83), which also validates the equivalent protein content of the two sample 
groups. 
These data, together with the G-protein activity measurements, indicates that the amount of 
CB1Rs binding sites and CB1Rs coupled to the G-protein increased as a result of chr nic KYNA 
treatment, without affecting the stimulatory or ligand binding of the receptor. 
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Table 4. The effect of long-term systemic KYNA treatment (i.p., 9 days, 128 mg/kg/day) on CB1R 
maximum binding capacity (Bmax) and binding affinity (dissociation constant; Kd) in saturation binding 
assays using [3H]WIN55,212-2 radioligand to detect CB1Rs in rat brain membranes. Data were obtained 
and analyzed from concentration-effect curves present d in Fig. 4 as described in section 2.5.     
  [3H]WIN55,212-2 saturation binding 
Treatment (n)  Bmax ± S.E.M. (fmol/mg) Kd ± S.E.M. (nM) 
Vehicle (4)   1339.25 ± 54.79 9.17 ± 1.04 
KYNA (4)  1879.09 ± 54.44*** 11.69 ± 0.91 
*:  significant difference compared to vehicle treaed (unpaired t test, 
two-tailed P value; ***: P < 0.001) 
 
 
 
 
Figure 4. The effect of long-term systemic KYNA treatment (i.p., 9 days, 128 mg/kg/day) on CB1R 
binding capacity and affinity compared to vehicle in rat brain membranes depicted in concentration-effect 
curves of [3H]WIN55,212-2 saturation binding assays. Figure represents the specific binding (inset figure: 
total and non-specific binding; indicated as ‘Total’ nd ‘NS’) of the radioligand in the presence of 
increasing concentration (0.13 - 65 nM) of the applied radioligand in vehicle and KYNA treated groups. * 
indicates the significant difference of individual concentration points between vehicle and KYNA treated 
samples (two-way ANOVA, uncorrected Fisher’s LSD; *: P < 0.05; ***: P < 0.001). Data are presented as 
means ± S.E.M. and were fitted as described in section 2.5. Saturation binding assays were performed as 
discussed in section 2.3.4. 
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3.5 Chronic systemic KYNA treatment significantly increases the amount of 
CB1R-coupled G-proteins in rat hippocampus, but not in the cortex and brainstem 
In the following experiments, we further investigated the brain region specificity of the 
obtained G-protein activity results from whole brain. Three main regions relevant to CB1R 
expression and function were chosen: cortex, hippocampus and brainstem. To detect CB1Rs only 
the agonist ACEA was used. It was found that compared to the vehicle group only the 
hippocampus displayed elevated levels of G-protein coupled CB1Rs, whereas in the cortex and 
brainstem its abundance remained unaltered (Fig. 5, Table 5). Similarly to the whole brain, the 
basal activity, the levels of ACEA-induced specifically bound [35S]GTPγS and the amount of 
maximum ACEA-stimulated G-protein coupled CB1Rs in the hippocampus was significantly 
enhanced as compared to the vehicle treated group (Fig. 5B, Table 5). The potency of the agonist 
ligand, as well as the maximum efficacy of the stimulated G-protein did not change significantly 
in the KYNA and vehicle treated groups (Fig. 5E, Table 5). Similar findings were observed in the 
cortex and brainstem too (Fig 5B and F, Table 5). The non-specific binding levels remained 
unaltered following the treatment in all three brain regions (Table 5). 
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Table 5. The effect of long-term systemic KYNA treatment (i.p., 9 days, 128 mg/kg/day) compared to 
vehicle on CB1R-coupled G-protein activity in rat cortex, hippocampus and brainstem described by the 
indicated parameters obtained from [35S]GTPγS binding assays. CB1R was stimulated by the highly CB1R 
selective agonist ACEA in increasing concentrations. The table highlights the non-specific binding (NS), 
basal activity (Basal) and maximum efficacy (Emax) levels of CB1R-coupled G-protein activity upon 
receptor stimulation given in specifically bound [35S]GTPγS of protein content. Emax levels and ligand 
potency (EC50) values were also calculated when data were normalized to basal activity levels (100 %) to 
see the overall performance of the ligand. Data were obtained from concentration-effect curves shown in 
Fig. 5 and statistically analyzed based on section 2.5.      
   Normalized to protein content  Normalized to basal activity 
Brain region Treatment (n) 
 NS ± S.E.M. 
(fmol/mg) 
Basal ± S.E.M. 
(fmol/mg) 
Emax ± S.E.M. 
(fmol/mg) 
 
Emax ± S.E.M. 
(%) 
EC50 ± S.E.M. 
(nM) 
Cortex Vehicle (3)  5.53 ± 0.18 60.09 ± 6.28 96.03 ± 12.69   159.8 ± 5.92 189.23 ± 74.34 
 KYNA (3)  5.47 ± 0.03  61.28 ± 3.39 97.96 ± 7.19  160.2 ± 6.4 243.22 ± 97.66 
Hippocampus Vehicle (6)  6.49 ± 0.44 84.7 ± 6.45 161.7 ± 8.71  193.1 ± 4.56 130.32 ± 24.69 
 KYNA (5)  7.42 ± 0.25 119.5 ± 4.46** 217.3 ± 11.93**  186.7 ± 6.28 161.81 ± 38.66 
Brainstem Vehicle (6)  9.91 ± 3.02 26.34 ± 2.84 36.39 ± 4.17  129.8 ± 1.92 91.41 ± 20.23 
 KYNA (4)  9.91 ± 4.49 26.52 ± 6.73 33.18 ± 9.55  130.3 ± 1.92 96.16 ± 22.88 
*: significant difference compared to vehicle treated (unpaired t test, two-tailed P value; **: P < 0.01) 
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Figure 5. The effect of long-term systemic KYNA treatment (i.p., 9 days, 128 mg/kg/day) on CB1R-
coupled G-protein activity compared to vehicle in rat cortex (A and D), hippocampus (B and E) and in 
brainstem (C and F) depicted in concentration-effect curves of [35S]GTPγS binding assays. CB1R was 
stimulated by the highly CB1R selective agonist ACEA. Figures represents the spcifically bound 
[35S]GTPγS of protein in fmol/mg (A-C) or in percentage normalized to basal activity leve s (100%) (D-
F) in the presence of increasing concentrations (0.1 nM - 10 µM) of ACEA. Data are presented as means ± 
S.E.M. Basal activity levels were determined in the absence of the indicated ligands. Dotted line 
represents basal activity levels. * indicates the significant difference of individual concentration points 
between vehicle and KYNA treated samples (two-way ANOVA, uncorrected Fisher’s LSD; **: P < 0.01; 
***: P < 0.001). Data were fitted as described under s ction 2.5, assays were performed as discussed in 
section 2.3.3. 
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3.6 Chronic systemic KYNA treatment enhances the CB1R maximum binding capacity in 
rat hippocampus without altering the binding affinity of the receptor 
To support our G-protein activity measurements in the hippocampus, we performed 
saturation binding assays in order to examine the maxi um binding capacity of CB1Rs in this 
brain region. The experimental setup was the same as d scribed in section 3.4. 
It was found that the KYNA treatment - as similarly seen in the whole brain - significantly 
increased the maximum binding capacity of the CB1Rs in the hippocampus, indicating a higher 
number of CB1R binding sites in this brain region of this group (Table 6. and Fig. 6). The Kd 
value of the radioligand did not change significantly, as well as the non-specific binding level, 
indicated by the significantly unaltered slope (Vehicle: 50.10 ± 1.25 vs. 52.34 ± 0.84; inset Fig. 
6). 
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Table 6. The effect of long-term systemic KYNA treatment (i.p., 9 days, 128 mg/kg/day) in rat 
hippocampus on CB1R maximum binding capacity (Bmax) and binding affinity (dissociation constant; Kd) 
in saturation binding assays using [3H]WIN55,212-2 radioligand to detect CB1Rs. Data were obtained and 
analyzed from concentration-effect curves presented i  Fig. 6 as described in section 2.5.     
  [3H]WIN55,212-2 specific binding 
Treatment (n)  Bmax ± S.E.M. (fmol/mg) Kd ± S.E.M. (nM) 
Vehicle (4)   1069.16 ± 96.83  13.39 ± 2.98 
KYNA (4)  1403.23 ± 75.36* 16.74 ± 2.07 
*:  significant difference compared to vehicle treaed (unpaired t test, 
two-tailed P value) 
 
 
 
 
 
 
 
Figure 6. The effect of long-term systemic KYNA treatment (i.p., 9 days, 128 mg/kg/day) in rat 
hippocampus on CB1R binding capacity and affinity compared to vehicle depicted in concentration-effect 
curves of [3H]WIN55,212-2 saturation binding assays. Figures represent the specific binding (inset figure: 
total and non-specific binding; indicated as ‘Total’ nd ‘NS’) of the radioligand in the presence of 
increasing concentration (0.59 - 64.5 nM) of the applied radioligand in vehicle or KYNA treated groups. * 
indicates the significant difference of individual concentration points between vehicle and KYNA treated 
samples (two-way ANOVA, uncorrected Fisher’s LSD; *: P < 0.05; **: P < 0.01). Data are presented as 
means ± S.E.M. and were fitted as described in section 2.5. Saturation binding assays were performed as 
discussed in section 2.3.4. 
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4 DISCUSSION 
A special attention has been given recently to the ov rlapping elements of the KP and the 
ECS and this field has been reviewed by our group and by others previously (Colín-González et 
al., 2016; Nagy-Grócz et al., 2017; Zádor et al., 2019). Our study focuses on two significant 
components of the KP and the ECS, the KYNA and the CB1R, respectively. Both elements are 
widely present throughout the body, however, the brain is where they have prominent roles and 
are most studied. In this work, we found for the first time, that enhanced CSF KYNA levels 
induced by systemic long-term KYNA treatment increas d the abundance of functional CB1Rs in 
whole brain, which is also manifested in the hippocampus. Importantly, this effect was indirect, 
as KYNA did not show affinity towards the CB1R. 
One of the key initial points of our current work was the well-known fact that KYNA is an 
endogenous agonist ligand for GPCR35, which similarly to the CB1R belong to the GPCR family 
and activates Gi/o-mediated signaling (Demuth and Molleman, 2006; Guo et al., 2007; Ohshiro et 
al., 2008; Wang et al., 2006). Thus, it was intriguin  to examine the binding and receptor 
activation capabilities of KYNA to the CB1R. Based on our binding studies KYNA did not bind 
directly to the CB1R, furthermore it did not alter the affinity of the CB1R specific ligand, ACEA. 
To examine the receptor activation (agonist, inverse agonist or antagonist) properties of KYNA 
on the receptor, we applied [35S]GTPγS binding assays. As mentioned in section 2.3.3, our 
experimental protocol is optimized for monitoring Gi/o-type G-proteins (DeLapp et al., 2004), 
which G-protein type is also stimulated by KYNA via GPR35 (Milligan, 2011; Wang et al., 
2006). Accordingly, agonist-stimulated CB1R coupled G-protein activity was unaltered in the 
presence of KYNA and the monitored G-proteins were not stimulated when only KYNA was 
present. These data, together with our receptor binding affinity results confirms that KYNA does 
not interact directly with the CB1R. Worthy of note, G-protein activity was measured in rat brain, 
where GPR35 receptors are sparsely expressed (Taniguchi et al., 2006), which is why we did not 
observe KYNA-stimulated GPR35 coupled G-protein activ tion in our samples. Additionally, the 
difference in the amino acid residues that form the binding pocket and that are responsible for 
agonist binding of CB1R and GPR35 (Krishna Kumar et al., 2019; Milligan, 2011; Zhao et al., 
2014) may explain why KYNA did not bind to the CB1R. Similar to other class A GPCRs, the 
binding pocket of CB1R and GPR35 is formed by almost the same transmembrane helix domains 
(3; 6 and 7) (Krishna Kumar et al., 2019; Milligan, 2011; Venkatakrishnan et al., 2013; Zhao et 
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al., 2014). However, compared to other GPCRs the agonist binding pocket of CB1R is further 
buried in the transmembrane domains of the receptor (Krishna Kumar et al., 2019), which may 
also contribute to the inability of KYNA to interact with the orthosteric binding site of the 
receptor. 
Previously our study demonstrated that systemic, high dose (128 mg/kg/day) long-term (9 
days) KYNA administration altered opioid receptor G-protein activity without directly binding to 
the receptor (Zádor et al., 2014b). Since cannabinoid and opioid receptors also share many 
features - including Gi/o type G-protein signaling and structure (Christie, 2006; Viganò et al., 
2005) - we investigated the effect of the same KYNA treatment on the CB1R. Before this, we 
examined whether the long-term systemic KYNA treatment altered brain (CSF) KYNA levels. 
KYNA – despites its relatively limited access to the CNS (Fukui et al., 1991) - can elicit central 
effects when administered systemically in large doses (Gill and Woodruff, 1990; Scharfman and 
Goodman, 1998) and can also increase the normally low nanomolar endogenous brain KYNA 
levels to micromolar concentration levels (Wu et al., 2000). Indeed, the applied dose of KYNA in 
our experiments was high, (128 mg/kg) and it signifcantly enhanced KYNA CSF levels 
compared to control. As expected, plasma KYNA levels a so increased after the treatment. 
Plasma and CSF KYNA levels in the vehicle treated group corresponded well with previous data 
(Wu et al., 2000). 
With the [35S]GTPγS binding assay we monitored CB1R-mediated G-protein activity, 
firstly in the whole brain of the rats, excluding the cerebellum to have an overall view of the 
effect of KYNA on central CB1Rs. This larger brain structure contains the cortex, hippocampus 
and brainstem. Our hypothesis was that in case we obs rve KYNA-induced alterations in CB1Rs 
in this structure, we would further analyze the brain region specificity of the effect in the cortex, 
hippocampus and brainstem, which are relevant regions f r CB1R function and expression (see 
later on). According to our data, KYNA administered in 128 mg/kg/day, i.p. after 9 days did not 
alter significantly the G-protein maximal efficacy nor the agonist ligand potency mediated via 
CB1R. Interestingly, in our previous study with opioid receptors the same treatment induced 
significant changes in these parameters brain region and opioid receptor type specifically (Zádor 
et al., 2014b). However, the amount of G-proteins at basal activity level significantly increased 
and so did the levels of CB1R coupled G-proteins, including those, which displayed maximum 
efficacy. This was observed both upon CB1R selective agonist and inverse agonist stimulation, 
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which concentration dependently increased and decreased G-protein basal activity, respectively 
(Kenakin, 2001). Since the protein levels of CB1R coupled G-proteins enhanced upon the 
treatment, the next step was to assess the amount of CB1R binding sites in saturation binding 
assays - from which the maximum binding capacity of the receptor can be analyzed. Accordingly, 
not only the amount of CB1R coupled G-proteins increased but the density (maxi um binding 
capacity) of the CB1R as well. Furthermore, the ligand binding of the receptor was not affected 
significantly by the treatment, and since binding affinity affects ligand potency, these results 
correspond well with the G-protein activity measurements, where ligand potency also remained 
unchanged. Thus, overall we can conclude that long-term KYNA treatment significantly 
increased the abundance of functional CB1Rs in the brain, without affecting the receptor binding 
and stimulation properties.  
In the next step, we analyzed the brain region specificity of the observed results. We chose 
the cortex, hippocampus and brainstem areas for multiple reasons. The cortex and brainstem 
covers significant areas of the rat whole brain, additionally the cortex region is rich in CB1Rs in 
contrast to the brainstem (Herkenham et al., 1990; Mackie, 2005). However, the brainstem - 
similarly to the cortex - mediate important functions relevant to CB1Rs, such as energy 
regulation, food intake and they are involved in certain psychiatric disorders too (Cota et al., 
2006; Desfossés et al., 2010). Despite the small dimensions of the rat hippocampus, it is one of 
the most densely populated brain region in terms of CB1Rs (Herkenham et al., 1990; Mackie, 
2005). Hippocampal CB1Rs for example have a significant role in cognitive functions (Pacher et 
al., 2006). Therefore, in our further experiments we applied G-protein activity measurements in 
the brain areas of our interest. With the same experimental setup, only the hippocampus showed 
the same changes as it was found in the whole brain. The amount of CB1R coupled G-proteins 
remained unaltered in the cortex and brainstem. Furthermore, in all brain regions the G-protein 
maximum stimulation and the potency of the applied s lective ligand showed no significant 
alteration. These results were further confirmed by saturation binding assays in the hippocampus, 
where the density of CB1Rs also significantly increased following the treatment, whereas the 
binding property of the receptor did not differ significantly in KYNA and vehicle treated 
samples. Additionally, in the investigated brain regions the level of specifically bound 
[35S]GTPγS and cannabinoid radioligand correlated well with earlier studies (Berrendero et al., 
2003; Mackie, 2005). Worthy of note, that hippocampus samples were only homogenized and no 
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membrane fractions were prepared from them. This wa necessary due to the small size of the 
brain region and also to limit the number of sacrifi ed animals for the assays. Nevertheless, the 
non-specific binding levels remained unaltered both in vehicle and KYNA treated samples, 
indicating that the overall protein content was the same. The receptor up-regulation seen in the 
whole brain was not entirely reflected by the changes observed in the hippocampus, most 
probably because other regions are involved apart from cortex, and brainstem, which can be 
potentially explored in a future study. Additionally, KYNA levels were also measured in the 
cortex, hippocampus and brainstem and we found no difference between vehicle and KYNA 
treated group (Table S2). Similar results were observed with L-KYN and tryptophan (Tale S2).  
One possible explanation for the up-regulation of brain CB1Rs can be a compensatory 
mechanism or neuroadaptation triggered by the long-term KYNA treatment. Such mechanisms in 
the brain have been previously proposed in certain conditions such as in rats withdrawn from 
palatable food cycling (Blasio et al., 2013), in patients with anorexia nervosa (Gérard et al., 2011) 
or posttraumatic stress disorder (Neumeister et al., 2015). Moreover, alterations in the ECS has 
been described in nearly all classes of diseases, and in certain pathological conditions CB1R up-
regulation can be protective as well as maladaptive (Miller and Devi, 2011). Brain KYNA levels 
can also be elevated in multiple neurological related disorders, which can either be 
neuroprotective or neurotoxic (Párdutz et al., 2012; Szalardy et al., 2012; Varga et al., 2015; 
Vécsei et al., 2013; Zádori et al., 2011a, 2011b). Regarding our study, schizophrenia is in 
particularly interesting, since patients suffering from such psychiatric disorder show elevated 
KYNA levels in the CSF and increased CB1R density in the brain (Erhardt et al., 2017; Ibarra-
Lecue et al., 2018). It is assumed that elevated endogenous brain KYNA level is a persistent 
condition in the brains of patients with schizophrenia (Nilsson et al., 2006), therefore we 
hypothesize that such permanent state may also evoke CB1R up-regulation - as we saw in our 
results - as a compensatory mechanism. Such hypothesis will be further investigated thoroughly 
by our group in the near future. 
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5 SUMMARY AND CONCLUSIONS 
In this study, we excluded for the first time the direct binding of KYNA to the CB1R. 
Moreover, we also found for the first time that long-term systemic high dose KYNA treatment 
enhanced the amount of functional CB1R binding sites in the whole brain, without affecting the 
overall activity and ligand binding of the receptor. Similar results were obtained from a more 
specific brain region, namely the hippocampus. The applied treatment also elevated KYNA levels 
in the CSF, indicating that KYNA is involved indirectly in the observed effects. These findings 
might reveal a possible connection between high KYNA CSF levels and increased brain CB1R 
density characterized by schizophrenia. 
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